Breaking News

CEVEC, UCB Ink AAV Mfg. Technology Agreement

UCB will use of CEVEC’s ELEVECTA AAV manufacturing technology in gene therapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CEVEC Pharmaceuticals GmbH signed an agreement with UCB S.A. for the use of CEVEC’s ELEVECTA Technology for the research, development, and manufacturing of Adeno-Associated Virus (AAV) vectors for gene therapy applications.   UCB has non-exclusive rights for research and development using ELEVECTA producer cell lines for specific transgenes selected by UCB. The agreement also grants UCB options to obtain licenses for use of the ELEVECTA producer cell lines in commercial manufacturing of potent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters